Drug Trial Radar · NCT05628740
Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175
Last checked: Nov 19, 2026Latest source record: Mar 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Feb 7, 2022
Primary completion
Oct 25, 2022
Study completion Oct 25, 2022
Sponsor
- Lead sponsor
- Nocion TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Nov 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Part 1 will evaluate the safety, tolerability and PK of single doses of three dose levels of NTX-1175 drug substance administered by dry powder inhaler (NOC-110) compared to a single dose reference nebulizer (NOC-100) treatment in healthy participants. Part 2 will evaluate the safety, tolerability and PK of multiple doses of NTX-1175 drug substance administered by dry powder inhaler (NOC-110) to participants with refractory chronic cough. Part 2 will also evaluate the treatment effect of multiple doses of one dose level of NTX-1175 drug substance administered by dry powder inhaler (NOC-110).
Conditions
- Refractory Chronic Cough
Interventions
3 mg NOC-100 (via nebulizer)Drug
Participants determined to be eligible for Part 1 of the study will be enrolled and will be assigned to receive a single dose of the reference nebulizer treatment of NOC 100 at 3 mg (Treatment A) in Period 1
1 mg NOC-110 (via DPI) [1x 1 mg capsule]Drug
Participants will be randomized to receive single doses of 1 mg NOC-110 (via DPI) in a crossover fashion according to a prespecified randomization schedule
3 mg NOC-110 (via DPI)Drug
Participants will be randomized to receive single doses of 3 mg NOC-110 (via DPI) in a crossover fashion according to a prespecified randomization schedule
Placebo (via DPI)Drug
Participants will be randomized to receive single doses of placebo via capsule in a crossover fashion according to a prespecified randomization schedule
6 mg NOC-110 (via DPI)Drug
Participants will be randomized to receive single doses of 6 mg NOC-110 via DPI in a parallel fashion according to a prespecified randomization schedule
Placebo (via DPI) [2x Placebo capsules]Drug
Participants will be randomized to receive single doses of Placebo (via DPI) \[2x Placebo capsules\] in a parallel fashion according to a prespecified randomization schedule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and severity of Treatment Emergent Adverse Events (TEAEs) following single doses of NOC-110 or placebo administered with a DPITime frame: Part 1- Screening through Day 23
- Number and severity of TEAE following repeat doses of NOC 110 compared to placebo in participants with chronic cough.Time frame: Part 2- Screening through Day 12
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Celerion
Phoenix, Arizona
Clinical Site Partners
Leesburg, Florida
Clinical Site Partners
Winter Park, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.